Patients' Wait for Etanercept May Be Over
The companies stated that notifications of product availability had been sent over the past eight weeks to patients on the etanercept waiting list, better known as the Enbrel Enrollment Program. The announcement apparently marks the first time this year that patients on the waiting list may actually receive the drug.
Amgen and Wyeth attributed the boost in the etanercept supply to "improved efficiencies at the current Enbrel manufacturing facility." The product has been in short supply since January 2001, and the companies have limited the distribution of etanercept to patients already receiving the long-term therapy.
Etanercept is indicated for the treatment of rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, and psoriatic arthritis.
According to today's announcement, the Enbrel Enrollment Program will continue to operate. Patients can enroll in the program by telephone at 888-436-2735.